Overview

Phase 3 Study of Yimitasvir Phosphate Capsules

Status:
Completed

Trial end date:
2019-06-25

Target enrollment:

Participant gender:

Summary

The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.

Phase:

Phase 3

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.

Treatments:

Sofosbuvir
Yimitasvir